Jennifer Lynne Fox, the Chief Legal & Corporate Strategy Officer at Myriad Genetics, recently acquired 39,370 shares of common stock. This transaction, reported on November 2, 2026, is significant as it showcases her ongoing commitment to the company.

Myriad Genetics operates in the in vitro and in vivo diagnostic substances sector, which plays a vital role in the healthcare industry. The acquisition of shares by a high-ranking officer like Fox may positively influence employee morale and investor perceptions regarding leadership stability.

According to the filing, the shares were acquired through time-based restricted stock units granted under the company's 2026 Employee, Director, and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in three equal annual installments, starting on the first anniversary of the grant date.

Following this transaction, Fox now owns a total of 345,334 shares of Myriad Genetics. This move may be viewed as a strong signal of confidence in the company's future prospects.

The filing does not say what happens next.

The transaction was classified under Form 4, which indicates that it was a non-derivative transaction. Jennifer Lynne Fox's acquisition of shares occurred on November 1, 2026, and the transaction code used was 'A', signifying an acquisition.

In addition to her role as Chief Legal & Corporate Strategy Officer, Fox's ownership of shares demonstrates her direct involvement and commitment to Myriad Genetics. The filing indicates that she holds her shares directly, as denoted by the 'D' in the ownership nature category.

Furthermore, the filing does not provide information regarding any previous transactions by Fox or any potential future plans for her holdings in Myriad Genetics.